Search Videos and More
News
“45 is the New 50” as Age for Colorectal Cancer Screening is Lowered
Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50.
Video
COVID-19 Vaccine Study in Cancer Patients
Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.
News
New ‘Druggable’ Genetic Targets Identified in Rare Type of Bile Duct Cancer
Scientists are beginning to make inroads into treating cholangiocarcinoma, a rare, lethal cancer of the bile ducts, with precision drugs. Last year, the first targeted drug for some patients with the disease was approved.
News
Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
News
2021 ASCO Highlights
Dana-Farber physician-scientists shared research and clinical advances at the 2021 Annual Meeting of the American Society of Clinical Oncologists (ASCO).
News
Hematologic Malignancies CME
The care of patients with hematologic malignancies is evolving rapidly. These video highlights will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).
News
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
News
Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer
A new partnership between researchers at Dana-Farber Cancer Institute and University College London (UCL) may prove decisive in the quest to develop the first blood test for early-stage ovarian cancer.
News
Dana-Farber Researchers Present Key Studies at ASCO Annual Meeting
Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
News
Immunotherapy Combination Shows Benefit for Patients with Advanced Melanoma, Phase 3 Trial Shows
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.
Document
Melanoma Select Clinical Trials
The listed trials are a sampling of our many open and accruing studies.
News
Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia
Leukemias involving reshuffling or rearrangement of the mixed lineage leukemia (MLL) gene, known as MLL-rearranged or MLL-r leukemias, account for 70 to 80 percent of acute leukemias in infants under one year old. In these blood cancers, a subset of acute myeloid and acute lymphoid leukemias (AML and ALL), the MLL gene breaks and reattaches to the wrong section of the chromosome.